Physicochemical properties and antifungal activity of amphotericin b incorporated in cholesteryl carbonate esters

Journal of Pharmaceutical Sciences

Volumn 100, Issue 5, 2011, Pages 1727-1735

  Chuealee, Rabkwan ^a   Wiedmann, Timothy Scott ^b   Srichana, Teerapol ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Aerosol; Anti infective; Dissolution; Solubility; Stability

Indexed keywords

AMPHOTERICIN B; CARBONIC ACID DERIVATIVE; CHOLESTEROL ESTER; CHOLESTERYL PALMITYL CARBONATE; DICHOLESTERYL CARBONATE; SODIUM CHOLESTERYL CARBONATE; UNCLASSIFIED DRUG;

AEROSOL; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CRYPTOCOCCUS NEOFORMANS; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; DRY POWDER; LIQUID CRYSTAL; NONHUMAN; PARTITION COEFFICIENT; PHYSICAL CHEMISTRY;

EID: 79952231531     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22398     Document Type: Article

References (30)

1. Bryskier A. 2005. Antimicrobial agents: Antibacterials and antifungals. Washington DC: ASM Press, pp 1288-1719.
2. Walsh TJ, Pezzo A. 1998. Treatment of systemic fungal infections: Recent progress and current problems. Eur J Clin Microbiol Infect Dis 7:460-475.
3. Sarosi GA. 1990. Amphotericin B: Still the 'gold standard' for antifungal therapy. Postgrad Med 88:151-152, 155-161, 165-166.
4. Denning DW, Stevens DA. 1990. Antifungal and surgical treatment of invasive fungal aspergillosis: Review of 2121 published cases. Rev Infect Dis 12:1147-1201.
5. Hung CT, Lam FC, Perrier DG, Souter A. 1988. A stability study of amphotericin B in aqueous media using factorial design. Int J Pharm 44:117-123.
6. Fukui H, Koike T, Saheki A, Sonoke S, Tomii Y, Seki J. 2003. Evaluation of the efficacy and toxicity of amphotericin B incorporated in lipid nanosphere. Int J Pharm 263:51-60.
7. Baas B, Kindt K, Scott A, Scott J, Mikulecky P, Hartsel SC. 1999. Activity and kinetics of dissociation and transfer of amphotericin B from a novel delivery form. AAPS PharmSci 1:1-11.
8. Gavaldà J, Martín MT, López P, Gomis X, Ramírez JL, Rodríguez D, Len O, Puigfel Y, Ruíz I, Pahissa A. 2005. Efficacy of nebulized liposomal amphotericin B in treatment of experimental pulmonary Aspergillosis. Antimicrob Agents Chemother 49:3028-3030.
9. Lowry CM, Marty FM, Vargas SO, Lee JT, Fiumara K, Deykin A, Baden LR. 2007. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: A retrospective study. Transplant Infect Dis 9:121-125.
10. Monforte V, Ussetti P, Gavaldà J, Bravo C, Laporta R, Len O, García-Gallo CL, Tenorio L, Solé J, Román A. 2010. Feasibility, tolerability and outcomes of nebulized liposomal amphotericin B for Aspergillus infection prevention in lung transplantation. J Heart Lung Transplant 29:523-530.
11. Shah SP, Misra A. 2004. Development of liposomal amphotericin B dry powder inhaler formulation. Drug Deliv 11:247-253.
12. Kuntsche J, Westesen K, Drechsler M, Koch MHJ, Bunjes H. 2004. Supercooled smectic nanoparticles: A potential novel carrier system for poorly water soluble drugs. Pharm Res 21:1834-1843.
13. Lin YY, Chen KS, Lin SY. 1996. Development and investigation of a thermo-responsive cholesteryl oleyl carbonate-embedded membrane. J Control Release 41:163-170.
14. Lin SY, Li MJ, Lin HL. 2000. Effect of skin-penetrating enhancers on the thermophysical properties of cholesteryl oleyl carbonate embedded in a thermo-responsive membrane. J Mater Sci Med 11:701-704.
15. Chuealee R, Wiedmann TS, Srichana T. 2009. Thermotropic phase behavior of sodium cholesteryl carbonate. J Mater Res 24:156-163.
16. Tiyaboonchai W, Woiszwillo J, Middaugh RC. 2001. Formulation and characterization of amphotericin B-polyethylenimine-dextran sulfate nanoparticles. J Pharm Sci 90:902-914.
17. Malmsten M. 2002. Surfactants and polymers in drug delivery. New York: Marcel Dekker, Inc, pp 19-25.
18. Pfaller M A. Diekema DJ, Rinaldi MG. 1996. Antifungal drugs: Mechanisms of action, drug resistance, susceptibility testing, and assays of activity in biological fluids. In Antibiotics in laboratory medicine; Lorian V, Ed. 5th ed. Baltimore: Lippincott Williams & Wilkins, pp 226-265.
19. Srichana T, Suedee R, Srisudjai P. 2003. Application of spectrofluorometry for evaluation of dry powder inhalers in vitro. Pharmazie 58:125-129.
20. Srichana T, Martin GP, Marriott C. 1998. On the relationship between drug and carrier deposition from dry powder inhalers in vitro. Int J Pharm 167:13-23.
21. Lavasanifar A, Samuel J, Kwon GS. Micelles self-assembled from poly(ethylene oxide)-block-poly(N-hexyl stearate-L-aspartamide) by solvent evaporation method: Effect on the solubilization and haemolytic activity of amphotericin B. J Control Release 77:155-160.
22. Aller AI, Martín-Mazuelos E, Gutiérrez MJ, Bernal S, Chávez M, Recio FJ. 2000. Comparison of the Etest and microdilution method for antifungal susceptibility testing of Cryptococcus neoformans to four antifungal agents. J Antimicrob Chemother 46:997-1000.
23. López-Jodra O, Torres-Rodríguez JM, Méndez-Vásquez R, Ribas-Forcadell E, Morera-López Y, Baró-Tomás T, Alia-Aponte C. 2000. In vitro susceptibility of Cryptococcus neoformans isolates to five antifungal drugs using a colorimetric system and the reference microbroth method. J Antimicrob Chemother 45:645-649.
24. Van Eldere J, Joosten L, Verhaeghe V, Surmont I. 1996. Fluconazole and amphotericin B antifungal susceptibility testing by National Committee for Clinical Laboratory Standards broth macrodilution method compared with E-test and semiautomated broth microdilution test. J Clin Microbiol 34:842-847.
25. Park BJ, Arthington-Skaggs BA, Hajjeh RA, Iqbal N, Ciblak MA, Lee-Yang W, Hairston MD, Phelan M, Plikaytis BD, Sofair AN, Harrison LH, Fridkin SK, Warnock DW. 2006. Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome. Antimicrob Agents Chemother 50:1287-1292.
26. Umegawaa Y, Matsumori N, Oishia T, Murata M. 2007. Amphotericin B covalent dimers with carbonyl-amino linkage: A new probe for investigating ion channel assemblies. Tetrahedron Lett 48:3393-3396.
27. Jung SH, Lim DH, Jung SH, Lee JE, Jeong KS, Seong H, Shin BC. 2009. Amphotericin B-entrapping lipid nanoparticles and their in vitro and in vivo characteristics. Eur J Pharm Sci 37:313-320.
28. Prime D, Atkins PJ, Slater A, Sumby B. 1997. Review of dry powder inhalers. Adv Drug Deliv Rev 26:51-58.
29. French DL, Edwards DA, Niven RW. 1996. The influence of formulation on emission, deaggregation and deposition of dry powders for inhalation. J Aerosol Sci 27:769-783.
30. Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew ML, Mintzes J, Deaver D, Lotan N, Langer R. 1997. Large porous particles for pulmonary drug delivery. Science 276:1868-1872.